Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Condition: Type 1 Diabetes Mellitus
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 1
Intervention: Technosphere® Insulin with MedTone C Inhaler; Technosphere ®Insulin with Gen2 Inhaler; Insulin Aspart in combination with a basal insulin
Intervention description: Inhalation Powder and injectable insulin; Inhalation Powder and injectable insulin; Injectable insulin
Intervention MeSH terms: Insulin; Insulin, Globin Zinc; Insulin Aspart
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 518.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      Open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of
      TI Inhalation Power in combination with a basal insulin versus insulin aspart in combination
      with a basal insulin
    

Eligibility criteria:

        Inclusion Criteria:

          -  Men and women = 18 years of age

          -  Clinical diagnosis of type 1 diabetes mellitus for at least 12 months

          -  Body mass index (BMI) = 38 kg/m2

          -  Stable dose of basal/bolus insulin therapy for at least 3 months with an FPG
             consistently < 220 mg/dL:

          -  HbA1c = 7.5% and = 10.0%

          -  Fasting C-peptide = 0.30 pmol/mL

          -  Subject willingness to not use CGM during the entire course of the trial

          -  Nonsmoking (includes cigarettes, cigars, pipes, and chewing tobacco) for the preceding
             6 months

          -  Negative urine cotinine test, defined as = 100 ng/mL

          -  Lung function tests: • Forced expiratory volume in 1 second (FEV1) = 70% Third
             National Health and Nutrition Examination Survey (NHANES III) predicted

          -  Written informed consent

        Exclusion Criteria:

          -  Total daily insulin dose = 2 IU/kg/day. History of insulin pump use within 3 months of
             Screening or use of continuous glucose monitoring within 6 weeks of Screening

          -  History of inhaled insulin use in the previous 6 months

          -  Two or more unexplained severe hypoglycemic episodes within 3 months of Screening or
             an episode of severe hypoglycemia between Visit 1 and Visit 2. Unexplained refers to
             episodes of severe hypoglycemia that are not related to a dosing error, lack of or a
             change in meal size, or related to additional/unanticipated exercise

          -  Any hospitalization or emergency room visit due to poor diabetic control within 6
             months of Screening, or hospitalization or emergency room visit due to poor diabetic
             control between Visit 1 and Visit 2

          -  Allergy or known hypersensitivity to insulin or to any of the drugs to be used in the
             study, or a history of hypersensitivity to TI Inhalation Powder or to drugs with a
             similar chemical structure

          -  History of recent blood transfusions (within previous 3 months), hemoglobinopathies,
             or any other conditions that affect HbA1c measurements.

          -  History of COPD, asthma, or any other clinically important pulmonary disease (eg,
             pulmonary fibrosis), or use of any medications for these conditions

          -  Any clinically significant radiological findings on screening chest x-ray

          -  Active respiratory infection within 30 days before Screening (subject may return after
             30 days from resolution for rescreening)

          -  Major organ system diseases, including: ? Seizure disorder; systemic autoimmune or
             collagen vascular disease requiring previous or current treatment with systemic
             corticosteroids, cytotoxic drugs, or penicillamine; cancer (other than excised
             cutaneous basal cell carcinoma) or any history of lung neoplasms

          -  Current or previous chemotherapy or radiation therapy that may result in pulmonary
             toxicity; use of medications for weight loss (eg, sibutramine, orlistat) within 12
             weeks of Screening; treatment with amiodarone within 12 weeks of Screening

          -  Clinically significant abnormalities on screening laboratory evaluation or chest x-ray

          -  Severe complications of diabetes, in the opinion of the PI, including symptomatic
             autonomic neuropathy; disabling peripheral neuropathy; active proliferative
             retinopathy; nephropathy with renal failure, renal transplant, or dialysis;
             nontraumatic amputations due to gangrene; or vascular claudication

          -  Women who are pregnant, lactating, or planning to become pregnant during the clinical
             study period; women of childbearing potential (defined as premenopausal and not
             surgically sterilized or postmenopausal for fewer than 2 years) not practicing
             adequate birth control. Adequate birth control is defined as using oral, percutaneous,
             or transdermal contraceptives; condoms and diaphragms (double barrier) with a
             spermicide; or intrauterine devices. Postmenopausal for this study includes amenorrhea
             f

          -  Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the
             opinion of the PI, would make the subject an unsuitable candidate for participation in
             the study

          -  Exposure to any investigational medications or devices within the previous 30 days
             before study entry

          -  Unable to read or write, or unlikely to comprehend and follow the study protocol
             procedures; lack of compliance with medication or procedures that, in the PI's
             opinion, may affect the study data or subject safety and that precludes the subject
             from participation in the study; or any other concurrent medical or major psychiatric
             condition that, in the opinion of the PI, makes the subject unsuitable for the
             clinical study or could limit the validity of the informed consent or impair the
             subject'